MedTrace Logo

A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer

NCT07597629 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2026-05-19

No results posted yet for this study

Summary

This is an open-label, multicenter Phase II clinical study conducted in subjects with advanced breast cancer.

Conditions

Interventions

DRUG

SYS6023

SYS6023 is a novel antibody-drug conjugate (ADC) targeting HER3, administered via intravenous infusion.

DRUG

HB1901

HB1901 is a specific mTOR inhibitor, administered via intravenous infusion.

DRUG

KN026

KN026 is an antibody targeting HER2, administered via intravenous infusion.

Sponsors & Collaborators

  • CSPC Megalith Biopharmaceutical Co.,Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-30
Primary Completion
2027-11-30
Completion
2029-05-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07597629 on ClinicalTrials.gov